Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q1 2020 · 10-Q
Revenue$571.64M$571.64M+3.2% vs Q1 2019 Net Income$685.90M$685.90M−20.7% vs Q1 2019 EPS Diluted$22.72$22.72−20.9% vs Q1 2019 Gross Profit$317,400,000+1.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flow$62,808,000+46.3% Free Cash Flowderived$41,217,000+113.4% Margins · derivedGross margin55.5%−0.8 pt vs Q1 2019
Operating margin13.0%+2.8 pt vs Q1 2019
Net margin120.0%
ended Mar 31, 2020 · filed May 8, 2020 · 38 d after period end